ArticleBMC pediatrics2026
Correlation between ceramide and its metabolites and central precocious puberty: a cross-sectional study.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmerging evidence suggests that ceramide (Cer) is implicated in obesity-associated central precocious puberty (CPP), potentially serving as a key mediator within hypothalamic pathways. This study investigated alterations in circulating Cer and its metabolites in CPP patients and explored their potential roles in CPP pathogenesis.
methodsIn this prospective cross-sectional study, 143 CPP patients and 140 healthy controls were enrolled. Clinical parameters, including gonadotropins, sex hormones, and Tanner stage, were assessed. Serum concentrations of total Cer, ceramide-1-phosphate (C1P), and sphingosine-1-phosphate (S1P) were quantified in a subset of 45 CPP patients and 30 controls.
resultsCirculating S1P levels were significantly elevated in children with CPP (P = 0.011). This association remained robust after adjustment for age and BMI (Model III). S1P was negatively correlated with total Cer (r = -0.321, P = 0.01) and mediated the association between Cer and CPP. Moreover, S1P showed significant interactions with BMI and serum 25-hydroxyvitamin D [25(OH)D], revealing a potential link between sphingolipid metabolism and pubertal regulation.
conclusionPeripheral S1P levels were markedly increased in CPP patients. S1P, rather than Cer, may represent a more sensitive biomarker for CPP and participate in the complex metabolic interplay involving BMI, vitamin D status, and pubertal initiation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.